Biogen resurrects Alzheimer's drug; shares jump 27%
October 22, 2019 at 17:08 PM EDT
Biogen Inc revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients suffering from the disease.